C vs TELO · P/E 16, rev $85.22B vs $86.0M cap
Citigroup Inc. (C) versus Telomir Pharmaceuticals, Inc. Common Stock (TELO) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Telomir Pharmaceuticals, Inc. Common Stock (TELO) is a biotechnology company listed on NASDAQ.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
TELO does not have a complete income-statement cache yet.
C currently screens at market cap $214.73B and trailing P/E 15.5. TELO currently screens at market cap $86.0M.
Not investment advice. Open the C and TELO stock pages for the full models.
Not investment advice.